OncoMatch/Clinical Trials/NCT05055648
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
Is NCT05055648 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for esophageal cancer.
The PROTECT trial will test the hypothesis that proton (PT) -enabled radiation dose reductions to sensitive, normal tissues will result in lower rates of treatment-related pulmonary complications in esophageal cancer compared to standard photon therapy (XT).
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1-4A, CN+, CM0 (TNM (8th edition))
Tumor stage according to TNM (8th edition): cT1-4a and/or cN+, cM0
Performance status
WHO 0–2
Prior therapy
Cannot have received: thoracic radiation therapy
Prior thoracic XT or PT
Cannot have received: chemotherapy
Prior ... chemotherapy ... in the esophageal/gastric region
Cannot have received: surgical resection in the esophageal/gastric region
Exception: previous EMR or ESD is allowed
Prior ... surgical resection in the esophageal/gastric region (previous EMR or ESD is allowed)
Lab requirements
Blood counts
hemoglobin > 90 g/L, absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L, platelets ≥ 75 x 10^9/L
Kidney function
creatinine ≤ 1.5 x ULN, GFR > 30 ml/min
Liver function
bilirubin ≤ 1.5 x upper limit of normal (ULN), ALAT ≤ 3 x ULN
Adequate laboratory findings: hematological: hemoglobin > 90 g/L, absolute neutrophil count (ANC) ≥ 1,5 x 109/L, platelets ≥ 75 x 109/L hepatic: bilirubin ≤ 1.5 x upper limit of normal (ULN), ALAT ≤ 3 x ULN renal: creatinine ≤ 1.5 x ULN, GFR (may be calculated) > 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify